OR WAIT null SECS
PAT is crucial to process control and real-time release in continuous manufacturing of solid-dosage drugs.
Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.
Appreciating the full impact certain select technologies will make on the industry by 2026.
June 01, 2023
WuXi Biologics is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.
May 31, 2023
The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.
API supplier Olon has started construction of a new manufacturing facility in Milan, Italy, which will be dedicated to production of cytotoxic payloads and linkers for ADCs.
Webinar Date/Time: Wed, Jun 21, 2023 2:00 PM EDT
Webinar Date/Time: Friday, June 23, 2023 at 11am EDT | 10am CDT | 8am PD
May 30, 2023
Webinar Date/Time: Thu, Jun 15, 2023 11:00 AM EDT
May 26, 2023
Myrna Wilson, director, Global Marketing, Strategic Growth and Technical Sales, Pharmaceutical Ingredients, Univar Solutions, discusses the state of the biopharma supply chain, movements in the patent industry, and more.
May 25, 2023
This agreement is intended to be executed and see the impact of any financial transfers by the fiscal year ending March 31, 2024.
Andrea Lodetti, CEO of Bormioli Pharma, an Italian pharma primary packaging manufacturer, speaks about his company's approach to the US market, supply chain instabilities, sustainability, and more.
May 23, 2023
uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.